Pittman Scott M. - 06 Oct 2026 Form 4 Insider Report for Nuo Therapeutics, Inc. (AURX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: AURX
Reported as of: 06 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Oct 2026, 18:11:53 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ David Jorden, attorney-in-fact

Filing notes and source

Key filing fact

Pittman Scott M. filed Form 4 for Nuo Therapeutics, Inc. (AURX) on 06 Oct 2026.

Key facts

This page summarizes Pittman Scott M.'s Form 4 filing for Nuo Therapeutics, Inc. (AURX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 06 Oct 2026, 18:11.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001674752 Primary reporting owner

Pittman Scott M.

Relationship: Director, 10%+ Owner
Address: C/O NUO THERAPEUTICS, INC., 8285 EL RIO, SUITE190, HOUSTON
Signature: /s/ David Jorden, attorney-in-fact
Signature date: 06 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AURX transaction Derivative

Second Restated Warrant (right to buy)

Award

Transaction value
Shares: +4,500
Change %
Price: $1.50^*
Shares after: 4,500
Date: 06 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,500
Exercise price: $1.50
Footnotes: F1

AURX transaction Derivative

Prepayment Restated Warrant (right to buy)

Award

Transaction value
Shares: +458
Change %
Price: $1.50^*
Shares after: 458
Date: 06 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 458
Exercise price: $1.50
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents Commitment, Origination Restated Second, and Capital Restate Second Warrants issued in connection with the assumption of a portion of an assigned funding commitment pursuant to the Assignment, Joinder, and Amendment No. 1 dated October 6, 2026 among the Issuer, the Reporting Person, and the other parties thereto (the "Amendment"), relating to the Amended and Restated Loan and Security Agreement dated May 29, 2026 (the "Loan Agreement"). The Reporting Person also holds a previously reported separate Second Restated Warrant that was issued and become exercisable on May 29, 2026.

Footnote F2

Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement, issued in connection with the assumption of a portion of an assigned commitment pursuant to the Amendment. The Reporting Person also holds a previously-reported separate Prepayment Restated Warrant that was issued on May 29, 2026, subject to the same vesting provision set forth in footnote (3) immediately below.

Footnote F3

Vesting (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2027, in accordance with the Loan Agreement.